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A Pharmacogenetic Prediction Model of 
Progression- Free Survival in Breast Cancer 
using Genome- Wide Genotyping Data from 
CALGB 40502 (Alliance)
Sara R. Rashkin1, Katherina C. Chua2, Carol Ho2, Flora Mulkey3, Chen Jiang3, Tasei Mushiroda4, 
Michiaki Kubo4, Paula N. Friedman5, Hope S. Rugo6, Howard L. McLeod7, Mark J. Ratain8, 
Francisco Castillos9, Michael Naughton10, Beth Overmoyer11, Deborah Toppmeyer12, John S. Witte1, 
Kouros Owzar3,13 and Deanna L. Kroetz2
Genome-wide genotyping data are increasingly available for pharmacogenetic association studies, but application of 
these data for development of prediction models is limited. Prediction methods, such as elastic net regularization, 
have recently been applied to genetic studies but only limitedly to pharmacogenetic outcomes. An elastic net was 
applied to a pharmacogenetic study of progression- free survival (PFS) of 468 patients with advanced breast cancer 
in a clinical trial of paclitaxel, nab- paclitaxel, and ixabepilone. A final model included 13 single nucleotide 
polymorphisms (SNPs) in addition to clinical covariates (prior taxane status, hormone receptor status, disease- free 
interval, and presence of visceral metastases) with an area under the curve (AUC) integrated over time of 0.81, an 
increase compared to an AUC of 0.64 for a model with clinical covariates alone. This model may be of value in 
predicting PFS with microtubule targeting agents and may inform reverse translational studies to understand 
differential response to these drugs.
Applications of genome-wide data beyond typical variant- by- 
variant association testing have been gaining popularity for 
pharmacogenetic phenotypes. Examples include gene- based or 
region- based tests,1,2 heritability analyses,3,4 transcriptome- based 
analyses,5–7 and polygenic risk scores.8–10 Another method is 
meta- analysis, combining summary statistics of multiple studies, 
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WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Pharmacogenetic studies using genome-wide genotyping 
data typically use association testing to identify SNPs that pre-
dict treatment response or toxicity. Models developed for accu-
rately predicting a pharmacogenetic outcome that include 
factors regardless of statistical association have not been widely 
applied to pharmacogenetic studies.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study used genome-wide genotyping data to develop a 
predictive model of PFS in patients with advanced breast cancer 
treated with microtubule targeting agents.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 A model that includes both clinical and genetic variables im-
proves the prediction of PFS with microtubule targeting agents 
compared to the use of clinical variables alone.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 This or other similar regularized regression approaches can 
be applied to other genome-wide genotype datasets to develop 
models to predict treatment outcome based on genetic profile.
Study Highlights
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but this can be difficult for pharmacogenetic phenotypes, in which 
different drugs, drug combinations, or patient populations are 
under study.11–13 Genome-wide data for pharmacogenetic pheno-
types have not been extensively used for developing models that 
will predict the treatment response, often involving many single 
nucleotide polymorphisms (SNPs) simultaneously, regardless of 
their statistical association with the outcome.14,15
In recent years, there have been an increasing number of genetic 
analyses using regularized regression methods, such as elastic net 
or least absolute shrinkage and selection operator (LASSO) re-
gression,14–17 Support Vector Machine algorithms,18 and random 
forest regression19 for developing a model  predicting outcome 
using multiple SNPs. Regularized regression methods have been 
applied to cell line studies for drug response,20–23 and there have 
been recent applications of such analyses in the prediction of du-
loxetine response.24 These models can improve prediction error 
and reduce overfitting as well as perform variable selection.18,25,26 
Although this type of modeling will not allow for inferences to be 
made regarding the strength of association between a SNP and 
the outcome of interest, a model can be developed that can aid in 
prediction. Here, we apply an elastic net model to a study focused 
on predicting progression- free survival (PFS) in patients with ad-
vanced breast cancer in a clinical trial of microtubule targeting 
agents.27
RESULTS
The clinical characteristics of the 468 genetic European patients in 
the primary analysis closely resembled the original trial population 
Table 1 Patient characteristics of clinical and pharmacogenetic cohorts
Paclitaxela Nab- paclitaxel Ixabepilone Total
Full 
cohort
EURc 
patients
non- EURd 
patients
Full 
cohort
EUR 
patients
Non- 
EUR 
patients
Full 
cohort
EUR 
patients
Non- EUR 
patients
Full 
cohort
EUR 
Patients
Non- EUR 
patients
Total 283 160 51 271 156 47 245 152 32 799 468 130
(0.35)b (0.34)b (0.39)b (0.34)b (0.33)b (0.36)b (0.31)b (0.32)b (0.25)b
Age, years
 20–49 69 36 14 76 33 18 73 47 10 218 116 42
(0.24) (0.23) (0.27) (0.28) (0.21) (0.38) (0.30) (0.31) (0.31) (0.27) (0.25) (0.32)
 50–69 183 106 31 163 104 26 154 92 21 500 300 78
(0.65) (0.66) (0.61) (0.60) (0.67) (0.55) (0.63) (0.61) (0.66) (0.63) (0.64) (0.60)
 70–80+ 31 18 6 32 19 3 18 13 1 81 59 10
(0.11) (0.11) (0.12) (0.12) (0.12) (0.06) (0.07) (0.09) (0.03) (0.10) (0.13) (0.08)
Taxane
 No 158 91 26 151 81 31 138 91 14 447 263 71
(0.56) (0.57) (0.51) (0.56) (0.52) (0.66) (0.56) (0.60) (0.44) (0.56) (0.56) (0.55)
 Yes 125 69 25 120 75 16 107 61 18 352 205 59
(0.44) (0.43) (0.49) (0.44) (0.48) (0.34) (0.44) (0.40) (0.56) (0.44) (0.44) (0.45)
Any visceral metastases
 No 55 34 8 60 30 16 42 31 2 157 95 26
(0.19) (0.21) (0.16) (0.22) (0.19) (0.34) (0.17) (0.20) (0.06) (0.20) (0.20) (0.20)
 Yes 217 126 43 205 126 31 199 121 30 621 373 104
(0.77) (0.79) (0.84) (0.76) (0.81) (0.66) (0.81) (0.80) (0.94) (0.78) (0.80) (0.80)
Disease- free interval
 ≤ 2 years 121 67 22 120 64 27 92 55 14 333 186 63
(0.43) (0.42) (0.43) (0.44) (0.41) (0.57) (0.38) (0.36) (0.44) (0.42) (0.40) (0.48)
 > 2 years 154 93 29 147 92 20 149 97 18 450 282 67
(0.54) (0.58) (0.57) (0.54) (0.59) (0.43) (0.61) (0.64) (0.56) (0.56) (0.60) (0.52)
Hormone receptor status
 Both 
negative
82 47 16 76 43 16 67 35 10 255 125 42
(0.29) (0.29) (0.31) (0.28) (0.28) (0.34) (0.27) (0.23) (0.31) (0.32) (0.27) (0.32)
 Either 
positive
201 113 35 195 113 31 178 117 22 574 343 88
(0.71) (0.71) (0.69) (0.72) (0.72) (0.66) (0.73) (0.77) (0.69) (0.72) (0.73) (0.68)
EUR, European.
aData reported as number of subjects (fraction of arm). bFractions of total samples rather than of arm. cGenetic European samples that were genotyped and 
passed quality control filters. dSamples that were genotyped and passed quality control filters but were not genetically European.
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(see Table 1). The median follow- up time in this European discov-
ery sample was 32.2 months, and there were a total of 406 observed 
disease progression events or deaths. A standard genome-wide 
association study (GWAS) was performed initially, using a Cox 
proportional hazards model to assess the effect of each SNP on 
PFS, stratified by treatment arm, and controlling for previously 
identified clinical covariates.27 For a significance threshold of 5E- 
8, no significant associations are detected. Therefore, an approach 
leveraging the strength of multiple SNPs collectively was applied 
to develop a prediction model.
Across the 10 models from the initial elastic net analyses, a me-
dian of 312 SNPs were retained (range: 263–340). The hazard 
ratios (HRs) ranged from 0.72−1.36, but the majority of SNPs 
remaining in each model had HRs between 0.95 and 1.05 (see 
Figure 1). Applying each model to the corresponding test set, the 
median area under the curve (AUC) collapsed across time is 0.78 
(range: 0.75–0.81). A model with only clinical covariates results 
in a median AUC of 0.62 (range: 0.60–0.65). Comparing across 
models, only a few SNPs were selected in all training sets. There 
are 832 SNPs that were selected in just a single model, but only 13 
SNPs were selected in all 10 (see Figure 2). Although some SNPs 
with larger effect sizes are selected only once or twice, these are rare 
exceptions. In general, the more often a SNP is selected, the less 
likely it is to be driven by only a few samples and the more likely it 
is to have a large effect size (see Figure 2).
A final model for prediction of PFS was created among all ge-
netic European samples with the clinical covariates and only the 
13 SNPs selected by all 10 initial models (see Table 2). For a val-
idation set of 130 non- European samples, AUC was calculated 
across varying time points. The median follow- up time in this non- 
European validation sample was 24.1 months, and there were a 
total of 113 observed disease progression events or deaths. A model 
with only clinical covariates was compared to a model with clinical 
covariates and the 13 SNPs (see Figure 3). Across the time period 
from 0−50 months, the model with only clinical covariates had an 
integrated AUC of 0.64 with a 95% confidence interval (CI) of 
0.60–0.67. Addition of the 13 SNPs to the model yielded an inte-
grated AUC of 0.81 (95% CI: 0.77–0.83). Across 10,000 simula-
tions of equivalent models with 13 randomly selected SNPs, only 
2,934 resulted in models retaining SNP covariates, none of which 
performed as well as our final model (median integrated AUC: 
0.64; range: 0.63–0.70).
Because the elastic net was used to construct our final model, 
many model diagnostics are not feasible. Using a standard Cox 
proportional hazard regression in lieu of the actual final model 
leads to similar effect sizes for all covariates. The proportionality 
assumption for all variables was tested and verified. Additionally, 
a deviance- like test was performed, and there was a significant 
(P < 2.2E- 16) reduction in model log- likelihood with the addition 
of the 13 SNPs compared with the model with clinical covariates 
alone.
DISCUSSION
Here, an elastic net approach was applied to develop a predic-
tion model of PFS in a clinical trial of paclitaxel, nab- paclitaxel, 
and ixabepilone in 468 genotyped patients with advanced breast 
cancer with European ancestry. The model was then validated 
in 130 genotyped patients with advanced breast cancer with 
non- European ancestry. Elastic net models reduce overfitting 
and perform variable selection, resulting in improved prediction 
error. Including genetic covariates improves the predictive ability 
(AUC = 0.81) compared with a model using only clinical covari-
ates (AUC = 0.64). Additionally, the SNP effect sizes are compa-
rable to or greater than those of the clinical covariates. The final 
model also validates the importance of controlling for multiple 
SNPs simultaneously, as it allows for inclusion of SNPs that are 
associated with both improved and worsened clinical outcome 
(see Table 2).
One limitation of this approach includes computational re-
sources. Although it is theoretically possible to include all SNPs 
genome-wide in the elastic net model, this is computationally bur-
densome. In order to reduce the computational load, only the top 
1,000 SNPs from a univariate analysis were used in the elastic net 
Figure 1 Distribution of hazard ratios for single nucleotide 
polymorphisms remaining in the model following elastic net 
regularization. The representative data are for one example fold from 
the cross- validation process. For ease of plotting, data were ordered 
by genomic position, but actual positions are not represented.
Figure 2 Comparison of median single nucleotide polymorphism 
(SNP) effect size by the frequency of SNP selection. The median 
hazard ratios (HRs) for each SNP selected in the models from the 10- 
fold cross- validations are plotted as a function of the number of folds 
selecting each SNP. The SNPs selected in all 10 folds were included 
in the final model.
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model. Whereas this ensures that the SNPs with the smallest P val-
ues are included in the elastic net model, SNPs with larger P values 
but important for prediction may be omitted from the final model. 
Screening based on univariate effect size rather than P value was 
considered, but the limited range of effect sizes led to more SNPs 
with lower effect sizes and fewer SNPs selected by all initial mod-
els. We also investigated the ideal number of SNPs to use in the 
elastic net and concluded that, for our data, 1,000 SNPs is optimal. 
Inclusion of < 1,000 SNPs led to a model that did not improve 
integrated AUC as much as the final model presented above, and 
> 1,000 SNPs had a negative effect on results, likely due to the ad-
dition of noise, hindering model optimization. Additionally, some 
of the SNPs remaining in the model have different minor allele 
frequencies in the European training and non- European valida-
tion sets (see Table 2), which could potentially affect the predic-
tion accuracy. However, the increase in AUC observed with the 
non- European samples suggests this prediction model is robust to 
population differences and genotype frequencies. Caveats of this 
approach are that elastic net methods require complete data, and, 
for the Cox proportional hazards implementation, it is not possi-
ble to stratify on a predictor. Finally, application of this method to 
other data may require optimization of the elastic net constraint 
parameter α.
The Cancer and Leukemia Group B (CALGB) 40502 tested 
whether newer microtubule- targeting agents showed improved 
PFS and/or toxicity in patients with locally recurrent or metastatic 
Table 2 Clinical variables and SNPs included in the final model for progression- free survival
Variable
Elastic net MAFa
Chromosome Position RefSeq annotationBeta HR EURb Non- EURc
Nab- paclitaxeld 0.19 1.21 — — — — —
Ixabepiloned 0.51 1.67 — — — — —
Disease- free 
intervale
−0.24 0.78 — — — — —
Visceral 
metastasesf
0.28 1.33 — — — — —
Prior taxaneg 0.50 1.65 — — — — —
Hormone receptor 
statush
−0.34 0.71 — — — — —
rs10490308 −0.38 0.68 0.12 0.096 2 75482375 TACR1
rs10516451 −0.32 0.72 0.40 0.25 4 100626549 MTTP
rs12440889 −0.41 0.66 0.12 0.096 15 38506692 SPRED1
rs12953016 0.31 1.37 0.14 0.49 17 52000308 KIF2B
rs17590916 −0.28 0.76 0.38 0.30 6 91344010 MAP3K7
rs419463 −0.26 0.77 0.32 0.16 3 128741642 CCDC48
rs4944458 −0.53 0.59 0.20 0.33 11 72088912 CLPB
rs5008836 0.32 1.37 0.38 0.51 1 79658861 ELTD1
rs540407 0.28 1.32 0.48 0.45 9 135343839 C9orf171
rs7812482 −0.27 0.77 0.37 0.18 8 76013093 CRISPLD1
rs897102 −0.31 0.74 0.17 0.24 11 8331494 LMO1
rs9859426 0.40 1.49 0.067 0.050 3 161523859 OTOL1
exm1431132 0.39 1.48 0.30 0.32 19 12774208 MAN2B1
EUR, European; HR, hazard ratio; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
aMinor allele frequency = observed frequency of least common allele in sample. bGenetic European samples that were genotyped and passed quality control 
filters (n = 468). cSamples that were genotyped and passed quality control filters but were not genetically European (n = 130). dCompared to paclitaxel. eGreater 
than 2 years, compared to ≤ 2 years. fPresence of visceral metastases compared to no visceral metastases. gPrior taxane compared to no prior taxane. hEither 
positive compared to both negative.
Figure 3 Model prediction of progression- free survival in non- 
European samples. The data represent the time- dependent area under 
the curve (AUC) and 95% confidence interval by month for the model 
with genetic information and clinical covariates compared to the model 
with only clinical covariates. SNP, single nucleotide polymorphism.
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breast cancer. The conclusion was that ixabepilone was inferior 
and nab- paclitaxel was not superior, with a trend toward inferior-
ity, compared with paclitaxel. Toxicity was also increased in experi-
mental arms. Because the two alternative therapies will not replace 
the standard- of- care paclitaxel, the prediction model developed 
here will have limited clinical utility in making treatment decisions 
between these three options. However, there may be some utility in 
making a prediction estimate for PFS in this setting when treated 
with paclitaxel.
Pharmacogenetic findings can also inform regarding the under-
lying mechanisms of drug response. Of the 13 SNPs remaining in 
the final model, several are annotated to genes that are plausibly 
related to the pharmacology of microtubule targeting agents, in-
cluding a kinesin family member and genes involved in mitogen- 
activated protein kinase signaling (see Table 2). The focus in 
prediction modeling is not on determining direct associations 
between a single SNP and the outcome of interest but, rather, on 
the collective predictive ability of multiple SNPs simultaneously. 
However, these genomic regions may be good candidates for fur-
ther exploration in clinical and molecular studies. Whether these 
variants or genomic regions might be interrogated for their con-
tribution to the poor response in the treatment arms of CALGB 
40502 would require further study. These same variables could 
also be the focus of reverse- translational studies to understand 
microtubule- targeting agents.
METHODS
Patients and drug response phenotype
Data collection was conducted by the Alliance Statistics and Data Center. 
Genotype and phenotype data were collected from CALGB 40502 
(NCT00785291), a phase III randomized three- arm study comparing 
nanoparticle albumin- bound (nab) paclitaxel or ixabepilone to paclitaxel 
(all given with bevacizumab) as first- line therapy for patients with advanced 
breast cancer. Trial design and outcome have been previously described.27 
CALGB is now part of the Alliance for Clinical Trials in Oncology. PFS 
was the primary end point. The analyses described here tested whether 
incorporating both clinical risk variables and genetic risk alleles provides 
an improved prediction model for PFS.
Genotyping and quality control
Genotyping and analysis of existing samples was approved by the 
National Cancer Institute Adult Central Institutional Review Board 
and by the Institutional Review Board at the University of California 
San Francisco. All participants provided written informed consent for 
pharmacogenetic sample procurement and analysis, and all studies were 
conducted in accordance with recognized ethical guidelines. From the 
799 patients randomized to the parent study, 633 consented to the 
pharmacogenetic substudy and had DNA available for genotyping 
(see Figure 4). DNA samples were genotyped using the Illumina 
HumanOmniExpressExome- 8 BeadChip at the Riken Center for 
Genomic Medicine, interrogating 964,055 SNPs with coverage of 
common variants and additional exonic content. All samples passed a 
low call rate filter (> 0.99). Two unintended duplicates were excluded. 
An X chromosome heterozygosity estimation identified three genetic 
males that were removed.
Figure 4 Quality control (QC) flowchart. The stepwise protocol for quality control analysis for samples and genotype data are presented. HWE, 
Hardy- Weinberg Equilibrium; IBD, identity-by-descent; MAF, minor allele frequency; PCA, principal component analysis; SNP, single nucleotide 
polymorphism.
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Figure 5 Overview of the statistical analysis. A 10- fold cross- validation in European (EUR) samples was used to create a final prediction model 
that was then tested in non- European samples. AUC, area under the curve; GWAS, genome-wide association study; SNP, single nucleotide 
polymorphism. 
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To avoid potential population stratification, principal component analysis 
(PCA) was performed using genotypes of all 628 patients to determine 
genetic ancestry with the GenABEL R package.28 A total of 485 patients 
of European genetic ancestry were identified and confirmed with a second 
PCA using the EIGENSTRAT method.29 Samples were excluded if any 
of the first three principal component vectors were outside two SDs of 
the mean values for patients self- reporting “White” race and “Non- 
Hispanic”/”Unknown” ethnicity, resulting in 478 samples for the primary 
analysis. SNPs were excluded using the following quality- control filters: 
minor allele frequency (MAF)  <  0.05, deviation from Hardy- Weinberg 
Equilibrium with P value  <  1E- 8, call rate  <  0.99, and nonautosomal, 
leaving 574,465 SNPs for analysis.
The analysis was further limited to the 468 genetic European patients who 
had complete data for PFS and all previously identified clinical covariates 
in the primary analysis from the clinical trial (prior taxane status, hormone 
receptor status, disease- free interval, and presence of visceral metastases).27 
PFS was defined as the time from registration until the date of the first 
disease progression or death from any cause, censoring at 50 months post- 
treatment in absence of an event or at the time of treatment discontinuation 
for any cause other than progression. To maintain complete data across 
all loci as required by the elastic net, SNPs with incomplete data were 
excluded, leaving 493,693 SNPs for analysis. An additional 130 non- 
European patients with complete data for the final model were reserved to 
evaluate model prediction.
Statistical analysis
To reduce the number of SNPs remaining in the model by chance alone, 
10- fold cross- validation was performed to create a final prediction model 
(see Figure 5). Ten initial models were created by subdividing the samples 
into 10 groups of approximately equal size. For each model, one group of 
samples was reserved for validation, so that each sample was used in exactly 
one test set. Each model was developed with the remaining samples as the 
training set.
To reduce the dimensionality in the elastic net regularization, the 1,000 
SNPs showing the strongest association with the trait were preselected 
for each model as follows. A variant- by- variant GWAS, using Cox 
proportional hazards regression with PFS as the outcome of interest and 
stratified by treatment arm, was performed on the training data. Regardless 
of whether a SNP attained genome-wide significance, the 1,000 SNPs 
with the smallest P values were retained.
For each training set, an elastic net Cox proportional hazards model was 
applied to the top 1,000 SNPs along with previously identified clinical 
covariates.27 Both variable selection and regularization to enhance 
prediction accuracy was performed via elastic net regularization using the 
glmnet R package.30,31 The elastic net model has two tuning parameters, α 
and λ.31 An α = 1 corresponds to the LASSO penalty and an α = 0 is the 
ridge penalty. To balance equally between ridge and LASSO regressions—
and both improve prediction by shrinking estimates to reduce overfitting 
and perform variable selection—a constraint parameter of α  =  0.5 was 
used. Cross- validation determined the optimal value of λ, using a pathwise 
coordinate descent. Solutions for 𝛽  were computed for a decreasing 
sequence of λ, starting with the smallest value for which all 𝛽   =  0. To 
account for the randomness in the cross- validation, the model was run 100 
times, and the error curves were averaged for each value of λ. The value of λ 
with the smallest mean cross- validation error was selected as the optimal λ. 
The AUC of each initial model was calculated using the reserved test data 
using the Song and Zhou estimator in the survAUC R package.32
The models created across all 10 training sets were compared, and SNPs 
remaining in all 10 models were retained. These SNPs were used to 
create a final model using all genetic European samples. The AUC of this 
model was calculated using 130 non- European samples from patients 
with complete data across all covariates using the same estimator 
described above. A bootstrap method was used to estimate a 95% CI 
for AUC. All analyses were conducted at the University of California, 
San Francisco.
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